secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-02-03T23:59:59+00:00
Accession:  0001178913-26-000289
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Silexion Therapeutics files 8-K disclosing corporate presentation for non-deal roadshow
--------------------------------------------------------------------------------

- Filed Form 8-K on February 3, 2026, with Items 7.01 and 9.01.
- Prepared a corporate presentation for use in investor meetings as part of a non-deal roadshow.
- Presentation furnished as Exhibit 99.1 and incorporated by reference.
- CEO Ilan Hadar signed the report on behalf of Silexion Therapeutics Corp.
- Presentation titled 'Silencing Oncogenes at the Level of Gene Expression' for Nasdaq: SLXN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326000289/0001178913-26-000289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326000289/zk2634285.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-000289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer